These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 20501838

  • 21. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer.
    Gu T, Ohashi R, Cui R, Tajima K, Yoshioka M, Iwakami S, Sasaki S, Shinohara A, Matsukawa T, Kobayashi J, Inaba Y, Takahashi K.
    Lung Cancer; 2009 Nov; 66(2):176-83. PubMed ID: 19285749
    [Abstract] [Full Text] [Related]

  • 22. The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo.
    Fujimori S, Abe Y, Nishi M, Hamamoto A, Inoue Y, Ohnishi Y, Nishime C, Matsumoto H, Yamazaki H, Kijima H, Ueyama Y, Inoue H, Nakamura M.
    Int J Oncol; 2004 Aug; 25(2):413-8. PubMed ID: 15254739
    [Abstract] [Full Text] [Related]

  • 23. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
    Tsai MF, Wang CC, Chang GC, Chen CY, Chen HY, Cheng CL, Yang YP, Wu CY, Shih FY, Liu CC, Lin HP, Jou YS, Lin SC, Lin CW, Chen WJ, Chan WK, Chen JJ, Yang PC.
    J Natl Cancer Inst; 2006 Jun 21; 98(12):825-38. PubMed ID: 16788156
    [Abstract] [Full Text] [Related]

  • 24. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression.
    Wehbe H, Kearney CM, Pinney KG.
    Anticancer Res; 2005 Jun 21; 25(6B):3865-70. PubMed ID: 16309172
    [Abstract] [Full Text] [Related]

  • 25. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells.
    Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R, Xiong S.
    Clin Cancer Res; 2005 Dec 01; 11(23):8273-80. PubMed ID: 16322285
    [Abstract] [Full Text] [Related]

  • 26. Expression of MAGE-D4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer.
    Ito S, Kawano Y, Katakura H, Takenaka K, Adachi M, Sasaki M, Shimizu K, Ikenaka K, Wada H, Tanaka F.
    Lung Cancer; 2006 Jan 01; 51(1):79-88. PubMed ID: 16225959
    [Abstract] [Full Text] [Related]

  • 27. [Class III beta tubulin expression in nonsmall cell lung cancer].
    Sève P, Dumontet C.
    Rev Mal Respir; 2010 Apr 01; 27(4):383-6. PubMed ID: 20403547
    [Abstract] [Full Text] [Related]

  • 28. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May 01; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 29. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer.
    Hofmann HS, Simm A, Hammer A, Silber RE, Bartling B.
    J Cancer Res Clin Oncol; 2002 Oct 01; 128(10):554-60. PubMed ID: 12384799
    [Abstract] [Full Text] [Related]

  • 30. [Role of Smac in cisplatin-induced apoptosis of non-small cell lung cancer cells].
    Cheng XD, Cai SX, Zhao HJ, Li WJ, Tong WC.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar 01; 28(3):389-91. PubMed ID: 18359697
    [Abstract] [Full Text] [Related]

  • 31. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome.
    Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG.
    Int J Mol Med; 2006 May 01; 17(5):937-44. PubMed ID: 16596284
    [Abstract] [Full Text] [Related]

  • 32. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.
    Oncol Rep; 2008 Sep 01; 20(3):581-7. PubMed ID: 18695909
    [Abstract] [Full Text] [Related]

  • 33. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells.
    Ikuta K, Takemura K, Kihara M, Naito S, Lee E, Shimizu E, Yamauchi A.
    Oncol Rep; 2005 Jun 01; 13(6):1229-34. PubMed ID: 15870947
    [Abstract] [Full Text] [Related]

  • 34. Aromatase inhibitors in human lung cancer therapy.
    Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM, Pietras RJ.
    Cancer Res; 2005 Dec 15; 65(24):11287-91. PubMed ID: 16357134
    [Abstract] [Full Text] [Related]

  • 35. Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides.
    Olbina G, Cieslak D, Ruzdijic S, Esler C, An Z, Wang X, Hoffman R, Seifert W, Pietrzkowski Z.
    Anticancer Res; 1996 Dec 15; 16(6B):3525-30. PubMed ID: 9042216
    [Abstract] [Full Text] [Related]

  • 36. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH, Wang SF, Yu L, Wang J, Chang H, Yan WL, Zhang J, Fu K.
    Lung Cancer; 2008 Oct 15; 62(1):113-9. PubMed ID: 18550205
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
    Weerasinghe P, Garcia GE, Zhu Q, Yuan P, Feng L, Mao L, Jing N.
    Int J Oncol; 2007 Jul 15; 31(1):129-36. PubMed ID: 17549413
    [Abstract] [Full Text] [Related]

  • 38. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ, Kong MJ, Ma ZY, Qian JF, Fan JQ, Xu XH.
    Zhonghua Yi Xue Za Zhi; 2007 Jun 05; 87(21):1506-9. PubMed ID: 17785094
    [Abstract] [Full Text] [Related]

  • 39. Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models.
    Zhang Q, Zhai S, Li L, Li X, Zhou H, Liu A, Su G, Mu Q, Du Y, Yan B.
    Biochem Pharmacol; 2013 Aug 01; 86(3):351-60. PubMed ID: 23743233
    [Abstract] [Full Text] [Related]

  • 40. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
    De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, Vellone V, Ferrandina G, Shahabi S, Scambia G, Ferlini C.
    J Cell Physiol; 2012 Mar 01; 227(3):1034-41. PubMed ID: 21520077
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.